中国组织工程研究
中國組織工程研究
중국조직공정연구
Journal of Clinical Rehabilitative Tissue Engineering Research
2015年
18期
2874-2878
,共5页
刘静%李立%冉江华%张升宁%李来邦%张熙冰%高扬%陈奕明
劉靜%李立%冉江華%張升寧%李來邦%張熙冰%高颺%陳奕明
류정%리립%염강화%장승저%리래방%장희빙%고양%진혁명
实验动物%消化系统损伤模型%减体积肝移植%肝脏%蛋白质组学%串联质谱分析%差异蛋白%能量蛋白%ATP合成酶
實驗動物%消化繫統損傷模型%減體積肝移植%肝髒%蛋白質組學%串聯質譜分析%差異蛋白%能量蛋白%ATP閤成酶
실험동물%소화계통손상모형%감체적간이식%간장%단백질조학%천련질보분석%차이단백%능량단백%ATP합성매
Liver Transplantation%Proteomics%ATP Synthase Complex%Energy Metabolism
背景:目前,蛋白质组学是一项比较成熟的科研技术,已经在肝移植基础研究领域中初步得到应用,但在大鼠减体积肝移植相关研究中的应用未曾报道。<br> 目的:应用蛋白质组学相关技术探讨大鼠减体积肝移植后与肝脏能量代谢蛋白相关的差异蛋白。<br> 方法:肝移植的供体是Lewis雌性大鼠,受体是Wistar雄性大鼠,供受体体质量差约20 g;移植肝质量/受体肝质量≈50%。采用改良减体积肝移植模型。获取供体肝组织过程中按照要求进行减体积,修整供体肝脏,将门静脉和肝下下腔静脉分别套入不同型号的套管以备套入受体的门静脉和肝下下腔静脉,胆道用细小支撑管植入供体的胆管中以备插入到受体的胆管中;最后进行受体的肝移植,受体先切除受体的原来肝脏组织,然后将准备好的供体肝脏植入受体中。造模后1,3和7 d获取移植肝脏组织,然后与预先获取冻存的供、受体肝脏组织应用蛋白组学技术建立双向凝胶电泳图谱,再利用串联质谱分析及数据库对差异表达的蛋白质点进行鉴定。<br> 结果与结论:采用变化倍数大于10倍为标准进行差异蛋白点的选择,结果总共发现了72个差异点,通过鉴定,最终32个蛋白的功能比较明确,其中有ATP合成酶β亚基、电子转化黄素蛋白β多肽和质子转运ATP合成酶3个蛋白参与了细胞能量代谢的过程,其分布于肝移植后的第1和7天,占6%。
揹景:目前,蛋白質組學是一項比較成熟的科研技術,已經在肝移植基礎研究領域中初步得到應用,但在大鼠減體積肝移植相關研究中的應用未曾報道。<br> 目的:應用蛋白質組學相關技術探討大鼠減體積肝移植後與肝髒能量代謝蛋白相關的差異蛋白。<br> 方法:肝移植的供體是Lewis雌性大鼠,受體是Wistar雄性大鼠,供受體體質量差約20 g;移植肝質量/受體肝質量≈50%。採用改良減體積肝移植模型。穫取供體肝組織過程中按照要求進行減體積,脩整供體肝髒,將門靜脈和肝下下腔靜脈分彆套入不同型號的套管以備套入受體的門靜脈和肝下下腔靜脈,膽道用細小支撐管植入供體的膽管中以備插入到受體的膽管中;最後進行受體的肝移植,受體先切除受體的原來肝髒組織,然後將準備好的供體肝髒植入受體中。造模後1,3和7 d穫取移植肝髒組織,然後與預先穫取凍存的供、受體肝髒組織應用蛋白組學技術建立雙嚮凝膠電泳圖譜,再利用串聯質譜分析及數據庫對差異錶達的蛋白質點進行鑒定。<br> 結果與結論:採用變化倍數大于10倍為標準進行差異蛋白點的選擇,結果總共髮現瞭72箇差異點,通過鑒定,最終32箇蛋白的功能比較明確,其中有ATP閤成酶β亞基、電子轉化黃素蛋白β多肽和質子轉運ATP閤成酶3箇蛋白參與瞭細胞能量代謝的過程,其分佈于肝移植後的第1和7天,佔6%。
배경:목전,단백질조학시일항비교성숙적과연기술,이경재간이식기출연구영역중초보득도응용,단재대서감체적간이식상관연구중적응용미증보도。<br> 목적:응용단백질조학상관기술탐토대서감체적간이식후여간장능량대사단백상관적차이단백。<br> 방법:간이식적공체시Lewis자성대서,수체시Wistar웅성대서,공수체체질량차약20 g;이식간질량/수체간질량≈50%。채용개량감체적간이식모형。획취공체간조직과정중안조요구진행감체적,수정공체간장,장문정맥화간하하강정맥분별투입불동형호적투관이비투입수체적문정맥화간하하강정맥,담도용세소지탱관식입공체적담관중이비삽입도수체적담관중;최후진행수체적간이식,수체선절제수체적원래간장조직,연후장준비호적공체간장식입수체중。조모후1,3화7 d획취이식간장조직,연후여예선획취동존적공、수체간장조직응용단백조학기술건립쌍향응효전영도보,재이용천련질보분석급수거고대차이표체적단백질점진행감정。<br> 결과여결론:채용변화배수대우10배위표준진행차이단백점적선택,결과총공발현료72개차이점,통과감정,최종32개단백적공능비교명학,기중유ATP합성매β아기、전자전화황소단백β다태화질자전운ATP합성매3개단백삼여료세포능량대사적과정,기분포우간이식후적제1화7천,점6%。
BACKGROUND:At present, the proteome is a mature technology that has been applied in basic research fields related to liver transplantation. But, it has been not reported in research related to reduced-size liver transplantation. <br> OBJECTIVE:To explore the expression of differential proteins related to hepatic energy metabolism fol owing reduce-size liver transplantation in rats by using by proteomic technology. <br> METHODS:The improved model of reduced-size liver transplantation was used in this experiment. The donor was health female Lewis rats and the recipient was male Wistar rats for liver transplantation. The difference between the donor and the recipient was about 20 g. The weight of donor liver/the weight of recipient donor was approximately equal to 50%. The donor liver tissue was harvested and trimmed to the required size. The portal vein and infrahepatic vena cava were cannulated, and the biliary tract was implanted into the donor bile duct for transplantation. Then the donor was transplanted into the recipient after the removal of original liver tissue. Hepatic specimens were harvested by 1, 3 and 7 days after reduced-size liver transplantation. Then, the harvested specimens were compared with the normal donor and recipient liver tissue that were previously harvested and frozen, to generate two-dimensional gel electrophoresis profile using proteome technology. Then tandem mass spectrometry and databases analysis were performed after two-dimensional electrophoresis for identifying differential protein stains. <br> RESULTS AND CONCLUSION:In this experiment, 72 differential protein stains with over lo-fold changes were selected. After identification, 32 proteins showed clear functions, and among them three differential proteins (ATP synthase beta subunit, electron-transferring flavoprotein beta peptide and proton-transferring ATP synthase) were involved in the process of cel energy metabolism. The proteins were distributed on 1 and 7 days after reduce-size liver transplantation, accounting for 6%.